SCIENTIFIC PROGRAM


MELANOMA BRIDGE 2019
Royal Continental Hotel, Naples, Italy
December 5th - December 7th, 2019




December 5th 2019


05.45 PM Registration **


Opening Session


06.45 PM Biomarkers for immunotherapy of cancer**, Magdalena Thurin
07.05 PM The struggle to understand failures and successes using immunotherapy in the treatment of cancer**, Giuseppe Masucci
07.25 PM Advocacy's Role in Educating Patients and Health Care Providers**, Valerie Guild






December 6th 2019


09.00 AM Introduction and objectives, Paolo A. Ascierto


Session - Melanoma as a model system
Chairpersons: Giuseppe Masucci, Nicola Normanno

09.10 AM Harnessing the gut microbiome to optimize cancer therapy, Laurence Zitvogel
09.30 AM The unsolved issues in treatment of melanoma in the adjuvant setting, Iman Osman
09.50 AM Emerging targets in the tumor microenvironment to improve radiotherapy and immunotherapy combinations, Sandra Demaria
10.10 AM Immunotherapy-Induced anti-cancer responses to the spectrum of "Cancer Antigens" and immune contraction, Bernard A. Fox
10.30 AM The role of Melanoma Derived Exosome in modifying the tumor microenvironment, Marc Ernstoff
10.50 AM Break **
11.00 AM Escape mechanisms in malignant melanoma, Soldano Ferrone
11.20 AM The model system for understanding checkpoint inhibitor resistance in cancer, Georgina V. Long
11.40 AM Electrochemotherapy in integrated approach of metastatic cutaneous melanoma, Corrado Caracò
12.00 PM New perspectives in uveal melanoma, Richard D. Carvajal
12.20 PM Oral Communications **
12.50 PM Symposium - The new approach to target therapy in Melanoma
12.50 PM Target Therapy: a new therapeutic paradigm for BRAF+ patients in adjuvant setting, Bart Neyns
01.10 PM Target Therapy: what further opportunities for BRAF+ patients in metastatic setting in the future?, Paolo A. Ascierto
01.30 PM Discussion on the new approach to target therapy in Melanoma, Paolo A. Ascierto, Bart Neyns
01.50 PM Lunch**


SESSION - Mechanisms of resistance and drivers of response
Chairpersons: Gerardo Botti, Giuseppe Palmieri

02.20 PM Symposium - Melanoma treatment practice changing. From metastatic disease to adjuvant: a new challenge
02.20 PM Adjuvant therapy: new opportunities, Mario Mandalà
02.40 PM Adjuvant therapy: emerging landscape in metastatic disease, Paolo A. Ascierto
03.00 PM Discussion about Melanoma treatment practice changing, Paolo A. Ascierto, Mario Mandalà
03.20 PM Translational research in the metastatic melanoma: recent results, Reinhard Dummer
03.40 PM Intrinsic tumor genomic and metabolic factors leading to immunoresistance, Patrick Hwu
04.00 PM Strategies to overcome resistance to the combination of MAPK and anti-PD-1 inhibitors, Roger Lo
04.20 PM Break**
04.30 PM Tumor mutation burden and liquid biopsies: helpful for treatment decisions?, Claus Garbe
04.50 PM Primary and secondary mechanisms of immunotherapy resistance, Thomas F. Gajewski
05.10 PM Next target for immune checkpoint blockade, Hassane M. Zarour
05.30 PM Histopathologic assessment of pre- and on-treatment specimens for predicting response to anti-PD-(L)1 therapy, Janis M. Taube
05.50 PM Discussion about Mechanisms of resistance and drivers of response, Giuseppe Palmieri, Gerardo Botti
06.00 PM Oral Communications **
06.45 PM Discussion about Oral Communication, Paolo A. Ascierto, Igor Puzanov, Corrado Caracò






December 7th 2019


Session - Emerging strategies
Chairpersons: Bart Neyns, Alexander Eggermont

09.00 AM Promising treatment strategies in early development, Reinhard Dummer
09.20 AM Adjuvant Therapy for High-risk melanoma - Current Status, Sanjiv Agarwala
09.40 AM Neoadjuvant Immunotherapy - the pathway to therapy personalization, Christian Blank
10.00 AM What combinations are really worth it?, Michael Postow
10.20 AM Transcriptional analysis of survival and T cell-inflammation nominates novel therapeutic Targets, Jason J. Luke
10.40 AM Break**
10.50 AM Il futuro: senza tentazioni, senza onore, Omid Hamid
11.10 AM Novel circulating biomarkers in melanoma, Ryan J. Sullivan
11.30 AM Oral Communications**
12.30 PM Symposium - IO adjuvant therapy and novel combination
12.30 PM A new paradigm: IO as adjuvant, Georgina V. Long
12.50 PM Novel combination strategies, Paolo A. Ascierto
01:10 PM Discussion on IO adjuvant therapy and novel combination, Paolo A. Ascierto, Georgina V. Long
01.30 PM Lunch **


Session - Great Debate
Chairpersons: Paolo A. Ascierto, Corrado Caracò, Alessandro Testori

02.00 PM Local vs systemic treatment, Sanjiv Agawarla, Olivier Michielin
02.30 PM Discussion on local vs systemic treatment, Sanjiv Agawarla, Olivier Michielin, Paolo A. Ascierto, Corrado Caracò, Alessandro Testori
02.40 PM Do we really need to treat stage IIIA patients with adjuvant: Yes or Not?, Alexander Eggermont, Jeffrey E. Gershenwald
03.10 PM Discussion on do we really need to treat stage IIIA patients with adjuvant?, Alexander Eggermont, Jeffrey E. Gershenwald, Paolo A. Ascierto, Corrado Caracò, Alessandro Testori
03.20 PM What time is better to change treatment: progression disease or stable disease?, Michael Postow, Omid Hamid
03.50 PM Discussion on what time is better to change treatment: progression disease or stable disease?, Michael Postow, Omid Hamid, Paolo A. Ascierto, Corrado Caracò, Alessandro Testori
04.00 PM Adoptive cell therapy before or in combination with check point inhibitors?, Hassane M. Zarour, Igor Puzanov
04.30 PM Discussion on adoptive cell therapy before or in combination with check point inhibitor, Hassane M. Zarour, Igor Puzanov, Paolo A. Ascierto, Corrado Caracò, Alessandro Testori
04.40 PM Can we stop the treatment on while response: Yes or Not?, Jean-Jacques Grob, Omid Hamid
05.10 PM Discussion on adoptive cell therapy before or in combination with check point inhibitor, Jean-Jacques Grob, Omid Hamid, Paolo A. Ascierto, Corrado Caracò, Alessandro Testori
05.20 PM Conclusions, Paolo A. Ascierto, Corrado Caracò, Igor Puzanov


* To be confirmed
** Not included in the CME accredited program


For information please contact info@melanomabridge.org